A Phase 1/2 Study of CB-103 (Oral Pan-NOTCH Inhibitor) With Abemaciclib or Lenvatinib in Combination in Patients With NOTCH Activated Adenoid Cystic Carcinoma (CALCulus)
Glenn J. Hanna
Summary
The goal of this study is to treat patients with NOTCH active advanced adenoid cystic carcinoma (ACC) tumors with a combination or two different oral medications to slow tumor growth and improve survival outcomes. The names of the study drugs involved in this study are: * CB-103 (an oral NOTCH pathway inhibitor) * Abemaciclib (CDK4/6 inhibitor) * Lenvatinib (a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI))
Description
This is a phase 2, open-label, non-randomized, parallel cohort, multicenter study investigating the novel pan-NOTCH inhibitor, CB-103, in combination with the CDK4/6 inhibitor, Abemaciclib, and CB-103 in combination with the multi-targeted vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI), Lenvatinib for patients with advanced, incurable, or metastatic adenoid cystic carcinoma (ACC) with a Notch pathway activating mutation. Participants will be placed into one of two treatment groups: Cohort 1: CB-103 + Abemaciclib or Cohort 2: VEGFR TKI Lenvatinib + CB-103.…
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Participants must meet the following eligibility criteria at the time of screening to be eligible to participate in the study: Eligibility Criteria 1. Participants must have histologically confirmed adenoid cystic carcinoma (ACC) with evidence of recurrent, metastatic or advanced, incurable disease arising from any primary site 2. Activating mutation in the NOTCH signaling pathway 3. In Cohort 1 only, prior multitargeted VEGFR TKI or systemic therapy is permitted. 4. In Cohort 2 only, no prior multitargeted VEGFR TKI therapy is permitted, but prior systemic chemotherapy as part of definitive…
Interventions
- DrugCB-103
First-in-class pan-NOTCH inhibitor, capsule taken orally.
- DrugAbemaciclib
CDK4/6 inhibitor, tablet taken orally.
- DrugLenvatinib
Per standard care, capsule taken orally.
Location
- Dana Farber Cancer InstituteBoston, Massachusetts